Key Points
- Director John Ryan bought 15,000 ASP Isotopes shares at an average price of $2.68, investing $40,200 and increasing his direct ownership to 675,222 shares. He also purchased 8,000 shares two days earlier at $2.70.
- ASP Isotopes reported a quarterly loss of $0.28 per share, missing the $0.17 consensus estimate, despite revenue of $5.12 million exceeding expectations. The company remains heavily unprofitable, with a negative net margin of 427.98%.
- Shares opened at $2.70, near the company’s 52-week low of $2.51 and well below its $14.49 high. Analyst sentiment is mixed, with a consensus “Hold” rating and a $13 average price target.
ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) Director John Ryan acquired 15,000 shares of the firm's stock in a transaction dated Wednesday, September 30th. The stock was bought at an average price of $2.68 per share, with a total value of $40,200.00. Following the acquisition, the director directly owned 675,222 shares in the company, valued at $1,809,594.96. This represents a 2.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.
Robert John Andrew Ryan also recently made the following trade(s):
- On Monday, September 28th, John Ryan bought 8,000 shares of ASP Isotopes stock. The stock was bought at an average cost of $2.70 per share, for a total transaction of $21,600.00.
ASP Isotopes Stock Performance
ASPI opened at $2.70 on Friday. ASP Isotopes Inc. has a 52-week low of $2.51 and a 52-week high of $14.49. The firm has a market capitalization of $413.94 million, a PE ratio of -2.05 and a beta of 3.70. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.85 and a current ratio of 3.87. The business's 50-day simple moving average is $3.72 and its 200 day simple moving average is $4.89.
ASP Isotopes (NASDAQ:ASPI - Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.11). The company had revenue of $5.12 million for the quarter, compared to analyst estimates of $4.47 million. ASP Isotopes had a negative net margin of 427.98% and a negative return on equity of 64.99%.
Hedge Funds Weigh In On ASP Isotopes
Institutional investors have recently bought and sold shares of the business. WINTON GROUP Ltd acquired a new stake in shares of ASP Isotopes in the second quarter valued at approximately $588,000. Integrated Wealth Concepts LLC bought a new position in shares of ASP Isotopes during the 2nd quarter worth approximately $176,000. Squarepoint Ops LLC increased its holdings in shares of ASP Isotopes by 75.6% during the 2nd quarter. Squarepoint Ops LLC now owns 123,951 shares of the company's stock worth $771,000 after acquiring an additional 53,354 shares during the last quarter. Amundi acquired a new position in shares of ASP Isotopes during the 2nd quarter worth approximately $107,000. Finally, AXQ Capital LP bought a new stake in ASP Isotopes in the 2nd quarter valued at $80,000. Institutional investors and hedge funds own 16.80% of the company's stock.
Analyst Ratings Changes
Several equities analysts recently weighed in on ASPI shares. Weiss Ratings reissued a "sell (d-)" rating on shares of ASP Isotopes in a research note on Monday, September 21st. Wall Street Zen raised shares of ASP Isotopes from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 22nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, ASP Isotopes currently has a consensus rating of "Hold" and an average price target of $13.00.
Check Out Our Latest Research Report on ASP Isotopes
ASP Isotopes Company Profile
(
Get Free Report)
ASP Isotopes Inc (NASDAQ: ASPI) is a development-stage company focused on isotope enrichment and related technologies. The company is developing an isotope-separation platform known as the Aerodynamic Separation Process, which is intended to enrich selected chemical elements and isotopes for use in several specialized markets.
ASP Isotopes has identified applications in the nuclear energy, medical, semiconductor, and quantum-computing industries. Its development programs have included uranium enrichment as well as the production of specialty isotopes such as carbon-14, molybdenum-100, and silicon-28.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
